文献速递骨软组织肉瘤与黑色素瘤支持与姑息治疗

难治性免疫检查点抑制剂相关结肠炎中的巨细胞病毒再激活

Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis.
PubMed 文献 · Eur J Cancer · 2017-10-19

该研究分析了2006至2016年间370例接受检查点抑制剂治疗的转移性恶性黑色素瘤患者,识别出41例免疫相关结肠炎(irColitis),其中5例(12.2%)对皮质类固醇和英夫利西单抗标准免疫调节治疗难治。所有难治性病例均可检测到巨细胞病毒(CMV),且难治性病例结肠活检和血浆中CMV-DNA检出率显著更高。结论强调对治疗难治性irColitis需重复诊断检测。

要点

  • 41例irColitis中5例(12.2%)对皮质类固醇和英夫利西单抗难治。
  • 所有难治性病例均可检测到CMV。
  • 难治性病例结肠活检和血浆CMV-DNA检出率显著更高。

核心结论

  • 本报告关于检查点抑制剂相关结肠炎管理中的CMV再激活,强调对治疗难治性irColitis需重复诊断检测。

研究设计与样本

  • 2006至2016年间在Essen大学医院皮肤科接受检查点抑制剂治疗的370例转移性恶性黑色素瘤患者中,识别所有数字病历记录有腹泻和/或结肠炎的患者。
  • 对标准免疫抑制治疗2周内无应答的患者归类为难治性。
  • 收集所有患者的人口学和临床数据。

主要发现

  • 识别出41例irColitis患者,多数发生在伊匹木单抗治疗期间。
  • 41例中5例(12.2%)对皮质类固醇和英夫利西单抗标准免疫调节治疗难治。
  • 难治性病例结肠活检显示更严重炎症(p = 0.04)。
  • 所有难治性病例均可检测到CMV。
  • 难治性病例结肠活检中CMV-DNA检出显著更频繁(p = 0.005),血浆中CMV-DNA检出显著更频繁(p = 0.002)。

临床怎么用

  • 对治疗难治性irColitis需重复诊断检测。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Immune checkpoint inhibitors can cause severe immune-related adverse events, with immune-related diarrhea and colitis (irColitis) being among the most frequent ones. While the majority of patients with irColitis respond well to corticosteroid treatment ± other immunomodulatory drugs such as infliximab, some patients do not show resolution of their symptoms. In the present study, we analysed the frequency of therapy-refractory irColitis, the underlying cause, and useful diagnostic approaches. METHODS: Between 2006 and 2016, 370 patients with metastatic malignant melanoma were treated with checkpoint inhibitors at the Department of Dermatology at the University Hospital Essen. All patients were identified for whom diarrhea and/or colitis was documented in the digital patient records. Patients who did not respond to standard immunosuppressive therapy within 2 weeks were classified as refractory. Demographic and clinical data of all patients were collected. RESULTS: We identified 41 patients with irColitis, the majority occurring during treatment with ipilimumab. Amongst these, 5 (12.2%) were refractory to standard immunomodulatory treatment with corticosteroids and infliximab. Therapy-refractory cases tended to show more severe inflammation in colonic biopsies (p = 0.04). In all therapy-refractory cases cytomegalovirus (CMV) was detectable. CMV-DNA in colonic biopsies and in plasma was significantly more often detectable in therapy-refractory cases (in colonic biopsies p = 0.005, in plasma: p = 0.002). Presence of serum CMV IgM and positive immunohistochemical stainings of colon biopsies for CMV were also associated with refractory colitis (p=0.021; p = 0.053). CONCLUSIONS: This report on CMV reactivation during management of checkpoint inhibitor-induced colitis emphasises the need for repetitive diagnostic measures in treatment-refractory irColitis.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Franklin C, Rooms I, Fiedler M, et al. Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. Eur J Cancer. 2017. PMID: 29055840. doi:10.1016/j.ejca.2017.09.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。